Androgen deprivation therapies (ADTs) and AR pathway inhibitors (ARPIs) are the standard care for advanced PCa, however, after temporary regression, tumors relapse is inevitable, and most patients acquire treatment-resistant phenotypes referred to as castration-resistant prostate cancer (CRPC) [2, 3]. This evidence concerns the gene AR and posterior cortical atrophy.